Recent Analysts’ Ratings Updates for Harmony Biosciences (HRMY)

Harmony Biosciences (NASDAQ: HRMY) recently received a number of ratings updates from brokerages and research firms:

• 8/4/2026 – Harmony Biosciences had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $70.00 price target on the stock.
• 8/4/2026 – Harmony Biosciences had its price target raised by Needham & Company LLC from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Harmony Biosciences had its price target raised by Mizuho from $50.00 to $51.00. They now have an “outperform” rating on the stock.
• 7/16/2026 – Harmony Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $55.00 price target on the stock.
• 7/13/2026 – Harmony Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/30/2026 – Harmony Biosciences had its price target raised by Deutsche Bank Aktiengesellschaft from $30.00 to $36.00. They now have a “hold” rating on the stock.
• 6/24/2026 – Harmony Biosciences had its “buy” rating reaffirmed by HC Wainwright.
• 6/23/2026 – Harmony Biosciences was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.